Major Symptoms Before 131I-MIBG Therapy and Therapeutic Response
| Symptoms before 131I-MIBG therapy | After 131I-MIBG therapy | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. | A | B | C | D | E | F | G | Symptomatic response | Elevated BP | BP response | Hormonal response | Tumor size response (RECIST) |
| 1 | + | + | + | + | + | − | − | Improved | + | + | PR | PR |
| 2 | − | − | − | − | − | − | − | No change (none to none) | − | − | Not elevated | StaD |
| 3 | + | − | + | − | − | − | − | Improved | − | − | StaD | StaD |
| 4 | − | − | − | − | − | − | + | Improved | − | − | Not elevated | PR |
| 5 | + | + | + | − | − | − | − | Improved | + | + | PR | PR |
| 6 | + | − | − | − | − | − | + | Improved | + | + | PR | StaD |
| 7 | − | + | + | − | + | − | − | Deteriorated | + | + | PD | PD |
| 8 | − | − | − | − | − | − | + | Deteriorated | − | − | PD | PD |
| 9 | − | − | − | − | − | − | − | No change (none to none) | − | − | StaD* | StaD |
| 10 | − | + | + | − | − | − | + | Improved | + | − | StaD | StaD |
| 11 | + | + | + | + | − | + | − | Improved | − | − | StaD | StaD |
| n | 5 (45.5%) | 5 (45.5%) | 6 (54.5%) | 2 (18.2%) | 2 (18.2%) | 1 (9.0%) | 4 (36.4%) | |||||
| PR (%) | 7/9 (77.8%) | 5/11 (45.5%) | 4/5 (80.0%) | 3/9 (33.3%) | 3/11 (27.3%) | |||||||
↵* Hormonal response was evaluated by plasma carcinoembryonic antigen and calcitonin.
A = headache; B = palpitations; C = sweating; D = irritation; E = insomnia; F = abdominal pain; G = pain; + = symptom observed; − = no symptom.
A–F are catecholamine-related symptoms; G is bone metastasis–related symptom.